Michael A Fifer
Overview
Explore the profile of Michael A Fifer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
2017
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Pavia P, Bilen O, Burroughs M, Costabel J, de Barros Correia E, Dybro A, et al.
JACC Heart Fail
. 2025 Feb;
13(2):346-357.
PMID: 39909646
Beta-blockers and nondihydropyridine calcium-channel blockers have been standard-of-care (SOC) medications for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), even though these agents do not directly affect the underlying pathophysiology of...
2.
Shin J, Small A, Blout Zawatsky C, Fifer M, Tower-Rader A, Green R, et al.
JACC Adv
. 2025 Jan;
4(2):101520.
PMID: 39886308
No abstract available.
3.
Osawa I, Akita K, Hasegawa K, Fifer M, Tower-Rader A, Reilly M, et al.
Circ Heart Fail
. 2025 Jan;
18(2):e012343.
PMID: 39831317
Background: Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy and causes major adverse cardiovascular events (MACE). SVEP1 (Sushi, von Willebrand factor type A, epidermal growth factor, and pentraxin domain containing...
4.
Akita K, Suwa K, Ohno K, Weiner S, Tower-Rader A, Fifer M, et al.
Int J Cardiol
. 2024 Dec;
421():132911.
PMID: 39706305
Background: Late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) in hypertrophic cardiomyopathy (HCM) typically represents myocardial fibrosis and may lead to fatal ventricular arrhythmias. However, CMR is resource-intensive and...
5.
Lu R, Lumish H, Hasegawa K, Maurer M, Reilly M, Weiner S, et al.
Eur J Heart Fail
. 2024 Dec;
27(2):275-284.
PMID: 39694602
Aims: Atrial fibrillation (AF) is the most common sustained arrhythmia among patients with hypertrophic cardiomyopathy (HCM), leading to increased symptom burden and risk of thromboembolism. The HCM-AF score was developed...
6.
Akita K, Maurer M, Tower-Rader A, Fifer M, Shimada Y
Circ Heart Fail
. 2024 Nov;
18(1):e012434.
PMID: 39523983
Background: Distinguishing hypertrophic cardiomyopathy (HCM) from other cardiomyopathies with left ventricular hypertrophy (LVH), such as hypertensive LVH, transthyretin amyloid cardiomyopathy, and aortic stenosis, is sometimes challenging. Using plasma proteomics profiling,...
7.
Ruran H, Wu A, Fifer M, Phipatanakul W, Alsulami S
Ann Allergy Asthma Immunol
. 2024 Nov;
134(1):102-103.
PMID: 39488778
No abstract available.
8.
Lumish H, Harano N, Liang L, Hasegawa K, Maurer M, Tower-Rader A, et al.
Europace
. 2024 Oct;
26(11).
PMID: 39441047
Aims: Atrial fibrillation (AF) is the most common sustained arrhythmia among patients with hypertrophic cardiomyopathy (HCM), increasing symptom burden and stroke risk. We aimed to construct a plasma proteomics-based model...
9.
Akita K, Kusunose K, Haga A, Shimomura T, Kosaka Y, Ishiyama K, et al.
Echo Res Pract
. 2024 Oct;
11(1):23.
PMID: 39396969
Background: Hypertrophic cardiomyopathy (HCM) can cause myocardial fibrosis, which can be a substrate for fatal ventricular arrhythmias and subsequent sudden cardiac death. Although late gadolinium enhancement (LGE) on cardiac magnetic...
10.
Sherrid M, Massera D, Bernard S, Tripathi N, Patel Y, Modi V, et al.
JACC Adv
. 2024 Sep;
3(10):101195.
PMID: 39280799
Background: There is controversy about risk of malignant arrhythmias and stroke in patients with apical aneurysms in hypertrophic cardiomyopathy (HCM). Objectives: The aim of this study was to estimate the...